CGM Benefits Selected Insulin-Treated Patients With Type 2 Diabetes In the second study, Andrew J Karter, PhD, of Kaiser Permanente Northern California, Oakland, and colleagues, retrospectively analyzed data from 5673 patients with type 1 diabetes and 36, 080 with type 2 diabetes who were taking insulin, mostly basal-bolus regimens.